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Purpose: To investigate the T cell inhibition potential of 50% ethanol extract of Cyperus scariosus (CS) 
and its bioactive chloroform fraction (CSC).   
Methods: The preliminary screening of the extract was carried out by humoral antibody response and 
delayed-type hypersensitivity models employing sheep red blood cells (SRBC) as the antigen. Further, 
the extract was studied by skin allograft rejection test, and phagocytosis - in vitro and ex vivo - by C. 
albicans method and carbon clearance test, respectively. The extract was fractionated with chloroform, 
n-butanol and water, and then used to investigate the T-cell specific immunosuppressive potential of 
these fractions by flow cytometry. 
Results: On p.o. administration, CS inhibited both humoral and cell-mediated immune responses 
significantly (p < 0.01) by suppressing primary (26.8 %) and secondary (29.7 %) antibody titres, and 
also inhibited cell-mediated delayed type hypersensitivity (DTH) immune response (45.9 %) at 600 
mg/kg dose,  phagocytosis - both in vitro (37.4 %) and ex vivo (37.8 %) - and delayed the graft rejection 
time (45.8%), thus confirming marked immunosuppression. Out of the three isolated fractions, only the 
chloroform fraction significantly (p < 0.01) suppressed CD8+/ CD4+ T cell surface markers (14.0/25.3 
%) and intra-cellular Th1 cytokines, viz, IL-2 (34.4 %), and IFN-γ (34.7 %), compared to cyclosporine-A 
(5), a standard T cell inhibitor (53.6 %) which was given to Balb/C mice at 200 mg/kg dose. CSC did not 
significantly (p < 0.01) suppress Th2 (IL-4) system.  
Conclusion: The findings from this investigation reveal that C. scariosus causes immunosuppression 
by inhibiting Th1 cytokines. 
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INTRODUCTION 
 
Cyperus sacriosus R. Br. (Family 
Cyperaceae), is an important medicinal plant 
in Indian Systems of Medicine and is 
indicated for inflammatory conditions of joints 
[1]. The present study was carried to 
investigate the immunomodulation potential 
of Cyperus scariosus (commonly known as 
Nagar motha in Hindi and Nagar musta in 
Sanskrit, Lawala in Marathi and Koraikkilangu 
in Tamil), which has been used in Indian 
Systems of Medicine (ISM) and by Ayurvedic 
practitioners for the treatment of 
inflammation, arthritis and stomach disorders 
[2]. The genus Cyperus is widely distributed 
throughout the world and consists of about 
700 species of which around 60 species 
occur in India. Some of them are used as 
fodder; a few, yielding culms and leaves, are 
used for matting, and yet others yielding 
tuberous rhizomes are used for edible, 
medicinal and perfumery purposes [3].  The 
plant has yielded many biogenetically 
important phyto-constituents.  
 
The chief chemical constituent of Cyperus 
scariosus is the essential oil, which is a 
mixture of at least 21 compounds, most of 
which are sesquiterpenes, such as cyperene, 
rotundene, rotundenol, isopatchoula-3,5-
diene, isopatchoul-3-ene, β-selinene, 
isopatchoulenol and scariodione. Ketones, 
hydrocarbons and a saponin have also been 
reported [4]. The essential oil of this plant has 
been found to be effective in treating 
exudative and proliferative phase of 
inflammation and also suppressed adjuvant 
induced arthritis [5]. This substantiates the 
folkloric usefulness of this plant in the Indian 
system of medicine.   In an in vitro study, it 
suppressed the spontaneous contractions of 
guinea pig paired atria, rat uterus and rabbit 
jejunum in a concentration-dependent 
manner, and also inhibited histamine and 
acetylcholine-induced contractions of guinea 
pig ileum, indicating non-specific spasmolytic 
action [6].  
 
Inspired by the therapeutic virtues of the plant 
and taking lead from its conventional uses, 
we have investigated the immunomodulation 
potential of Cyperus scariosus extract (CS) 
and its corresponding chloroform fraction 
(CSC) as well as its putative role in alleviating 






C. scariosus roots were collected from the 
local market of Sagar, Madhya Pradesh, 
India and authenticated by routine 
pharmacognostic procedures by Dr BK 
Kapahi, Senior Botanist, Indian Institute of 
Integrative Medicine (IIIM), Jammu, India. A 
voucher specimen was retained and 
deposited at the crude drug repository of the 
herbarium of IIIM, vide CDR accession no. 
3234. The test material was prepared as 
fresh suspensions using 1% sterile gum 
acacia in sterilized distilled water. 
 
Preparation of extract and fractions 
 
Cyperus scariosus roots (2 kg) were 
macerated with ethanol : water (1:1) with 
constant stirring at 1200 rpm at room 
temperature for 3 h. The extract was filtered 
and the marc was drained. The marc was 
subjected to the same extraction procedure 
thrice to complete extraction. The combined 
extract was reduced to 1/8
th 
of its original 
volume with a rotary evaporator (Heidolph 
Laborota 4000) at 50°C and lyophilized 
(Telstar Lyobeta 35), giving a yield of 186 g. 
The lyophilized extract was macerated with 
chloroform, and the chloroform-soluble 
portion was separated and evaporated on a 
rotavapor to obtain the chloroform fraction 
which weighed 8.26 g. The chloroform 
insoluble portion was partitioned between n-
butanol and water to obtain n-butanol (53.42 
g) and water (124.32 g) fractions. 
 
Animals 
Male Balb/C mice (Mus musculus) 8–10 
weeks old and weighing 18–22 g, in groups 
of six, were used for the study. The protocol 
for acute toxicity and ex vivo studies on 
immunomodulatory activity was approved by 
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Institutional Animal Ethics Committee (IAEC) 
of Dr. HS Gour University, Sagar, M.P. 
(CPCSEA registration No. 379/01/ab/ 
CPCSEA; vide approval no. Animal 
Eths.Comm./DB/98). The animals were 
housed under standard laboratory conditions 
- 23 ± 1 °C, 55 ± 10% relative humidity, 12/12 
h light/dark cycles, fed with standard pellet 
diet (Lipton India Ltd) and received water ad 
libitum. None of the animals was sacrificed 
throughout the study; however, as per the 
institute’s norms, the animals, after 
experimentation, were subjected to 
euthanasia by a high inhalational dose of 
diethyl ether and disposed off by incineration. 
Drugs 
 
i) Drugs for oral administration were freshly 
prepared as a homogenized suspension of C. 
scariosus extract (CS) in doses of 50,100, 
200, 400, 600 and 800 mg/kg and C. 
scariosus chloroform fraction (CSC) in doses 
of 25, 50, 100, and 200 mg/kg in 1% w/v 
acacia gum and administered orally to Balb/C 
mice once daily for the duration of the 
experiment.  
 
ii) Cyclophosphamide and cyclosporine-A 
were used as standard immunosuppressive 
agents at doses of 250 and 5 mg/kg p.o. for B 




Fluoroisothiocyanate (FITC)-labeled CD4 
anti-mouse monoclonal antibody, phyco-
erytherin (PE)-labeled CD8 anti-rat 
monoclonal antibody, FACS lysing solution, 
FACS permeabilising solution, Golgi plug, IL-
2 monoclonal antibody anti-mouse (PE), IFN-
γ- monoclonal antibody anti-mouse (FITC), 
TNF-α- monoclonal antibody anti-rat (BD 
Biosciences); phosphate buffer saline, 
ethylene diamine tetraacetic acid (EDTA) 
(Sigma Aldrich), and heparin (Sigma Aldrich) 





Fresh sheep red blood cells (SRBC) collected 
aseptically from the jugular vein of sheep 
stored in cold sterile Alsever's solution, were 
washed three times with pyrogen-free sterile 
normal saline (0.9% NaCl). Cell count was 
adjusted to 5×10
9 
cells/mL for immunisation 




On specified days, as per the protocol, blood 
was drawn from retro-orbital plexus of the 
animals into a sterile tube with EDTA as an 
anti-coagulant. 
 
General behavior and acute toxicity test 
 
Acute oral toxicity studies were carried out 
following OECD guidelines no. 423 [7]
 
after 
approval from the Institutional Animal Ethics 
Committee (IAEC). Three female Balb/C 
mice, fasted 3 - 4 h prior to the test,  were 
used for each step and observed individually 
after dosing at least once during the first 30 
min, and periodically during the first 24 h, 
with special attention given during the first 4 
h, and daily thereafter, for a total of 14 days. 
Simultaneously, general behavior and any 
toxic symptoms produced by the test material 
were observed for 14 days for routine 
pharmacological parameters such as 
cyanosis, tremors, convulsions, ataxia, body 
tone, muscle tone, piloerection, salivation, tail 
flick, drowsiness, alertness, spontaneity, 
diarrheoa, pupil size, ptosis, breathing rate, 
urination etc.  
 
Selection of doses 
 
No toxic symptoms were observed in mice up 
to 2000 mg/kg p.o. dose (LD0). Evaluation of 
the test material was initiated by giving to the 
mice 1/10
th
 of this dose (200 mg/kg) as well 
as lower (100 mg/kg) and higher (400 mg/kg) 
doses. It was observed that the effect 
increased significantly (p<0.01) at 400 mg/kg 
dose and, therefore, higher doses (600 and 
800 mg/kg) were also explored.  
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Humoral antibody response 
 
Mice (n = 6) were immunised by injecting 200 
µL of 5 × 10
9
 SRBC/mL intraperitoneally (i.p) 
on day 0. C. scariosus extract (CS) was 
administered to the mice in graded doses 
(50, 100, 200, 400, 600 and 800 mg/kg body 
wt) for seven days. The blood samples were 
collected on day +7 (before challenge) for 1
o
 
Antibody titre and on day +14 (7 days after 
challenge) for 2
o
 Antibody titre. 
Hemagglutination Antibody titres were 
determined following the micro-titration 
technique [8]. BSA-saline served as control. 
 
Delayed-type hypersensitivity (DTH) 
response  
 
CS at doses of 50, 100, 200, 400, 600 and 
800 mg/kg p.o. was administered after SRBC 
sensitization to mice and once daily on 
consecutive days. Six days later, the 
thickness of the left hind foot was measured 
with a spheromicrometer (pitch, 0.01 mm) 
and was considered as a control. The mice 
were then challenged by injecting the same 
amount of SRBC intra-dermally into the right 
hind footpad. The foot thickness was 
measured again after 24 h [9]. 
 
Skin allograft rejection 
 
The 50% ethanol (EtOH) extract of C. 
scariosus (CS) was administered to mice at 
doses of 50 -800 mg/kg for 7 days and graft 
rejection time (GRT) was recorded by daily 
observations of epithelial skin layer survival. 
Control group was given only vehicle and 
another group received cyclosporine-A as 
standard at 5 mg/kg daily for 7 days [10]. 
 
 
In vitro phagocytic response  
 
The phagocytic function of peritoneal 
macrophages were assessed by harvesting 
murine peritoneal macrophages by flushing 
the peritoneal cavity with 5 ml of sterile ice 
cold 0.15 mM phosphate buffer saline (PBS) 
containing 2 units/ml of preservative free  
heparin. The number of viable nucleated cells 
was determined by trypan blue dye exclusion 
test in a hemocytometer. The cells from the 
suspension were allowed to adhere to glass 
cover slips for 2 h at 37 °C in 5% CO2 
incubator with 50-800 µg/ml concentrations of 
PL (Group III-VIII), 10 µg/ml concentration of 
cyclosporine-A. Group I served as control. 
 
The non adherent cells were washed with 
PBS and heat-killed Candida albicans cells 
opsonized with 20% mouse serum for 90 min. 
An aliquot (100 µl) of these C. albicans cells 
was incubated with macrophages and 
incubated for 15 min at 37 °C in 5% CO2 and 
95% RH. The cover slips were washed 
thoroughly with PBS and stained with trypan 
eosin. The percentage and average number 
of Candida albicans cells (heat-killed) 
ingested by peritoneal murine macrophages 
were calculated [11]. 
 
Ex vivo phagocytic response 
 
The phagocytic function of the 
reticuloendothelial system was assayed in 
groups of six mice each by injecting i.v. 160 
mg/kg of 1.6% suspension of gelatin 
stabilized carbon particles of 20–25 µm size 
[12]. Blood samples were collected before 
carbon injection and at intervals varying 
between 2 and 90 min thereafter. An aliquot 
(10 µL) of the blood samples was lysed with 
2 mL of 0.1% acetic acid and its transparency 
determined spectrophotometrically at 675 nm 
(Uvikon 810, spectrophotometer, Kontron Ltd, 
Switzerland). CS was administered orally for 
7 days and 30 min prior to the carbon 
injection in a dose range of 50-800 mg/kg 
[13]. 
 
Evaluation of T cell surface markers by 
flow cytometry 
 
For T cell surface markers estimation, mice in 
groups (I to VII) were immunised on day 0 by 
injecting 200µL of 5 x 10
9
 SRBC/mL 
intraperitoneally (i.p). C. scariosus chloroform 
fraction (CSC) at doses of 25, 50, 100 and 
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200 mg/kg, respectively (Groups IV – VII) and 
cyclosporine-A (Group III) at a dose of 5 
mg/kg, were administered for +7 days 
including the day of immunisation. On +8 
day, the animals from groups II – VII were 
challenged with sheep RBCs (SRBC). On 
+10 day, the animals were bled retro-orbitally 
and blood was collected in EDTA-coated 
tubes for CD4+/CD8+ T cell surface markers 
estimations. Group I served as normal control 
(NC) and Group II as sensitized control (SC). 
  
Lymphocyte subsets were measured by 
immunofluorescent antibody staining of whole 
blood and subsequently analysed using two-
colour flow cytometry (Becton & Dickinson, 
UK). Murine monoclonal antibodies 
conjugated to a fluorochrome and directed 
against receptors CD4 and CD8 were used 
for the study. The fluorochrome-labeled 
monoclonal antibodies were added directly to 
100 µL of whole blood, which was then lysed 
using whole blood lysing reagent (BD 
Biosciences). Following final centrifugation, 
samples were re-suspended in phosphate-
buffered saline (pH 7.4)
 
and analyzed directly 
on the flow cytometer (LSR, BD Biosciences) 
using Cell Quest Pro Software (BD 
Biosciences). A fluorescence trigger was set 
on the FITC (FL1) parameter to analyze 
CD4+ and PE (FL2) parameter to collect 
CD8+ events [14]. 
 
Estimation of intracellular cytokines by 
flow cytometry 
 
Mice in groups (I to VII) were immunised on 
day 0 by injecting 200µL of 5 x 10
9
 SRBC/mL 
intraperitoneally (i.p.). CSC at doses of 25, 
50, 100 and 200 mg/kg (Groups IV – VII) and 
cyclosporine-A at a dose of 5 mg/kg (Group 
III) were administered for +7 days including 
the day of immunization. On +8 day, the 
animals from groups II – VII were challenged 
with sheep RBCs (SRBC). On +10 day, the 
animals were bled retro-orbitally and blood 
was collected in EDTA-coated tubes for the 
estimation of Th1 cytokines, such as IL-2 and 
IFN-γ, and Th2 cytokine, IL-4 [15]. Group I 
served as normal control and Group II as 
sensitised control. Analysis was done on a 




Data were expressed as the mean ± standard 
error of the means (S.E.) for six mice per 
group, and statistical analysis was carried out 
using Dunnett test with the aid of Instat 3 
software. 
 
RESULTS   
 
Prior to the animal experiments, toxicity 
studies were carried out for dose 
standardisation, in which it was observed that 
LD0 of CS was 2000 mg/kg dose and none of 
the animals showed toxic signs and 
symptoms. 
 
Humoral antibody response 
 
CS, on oral administration at doses ranging 
from 50 - 800 mg/kg, produced a dose-
related decrease in primary antibody 
formation. However, maximum effect was 
observed at 600 mg/kg (26.8 % decrease) 
after which the suppressive effect waned to 
22 % at 800 mg/kg oral dose. 
Cyclophosphamide (as standard) showed 
31.8 % decrease in the antibody formation at 
a dose of 250 mg/kg (Table 1). CS more 
effectively decreased secondary antibody 
production, in which the maximum 
suppression (29.7 %) was noticed at 600 
mg/kg dose. Cyclophosphamide decreased 
antibody formation by 36.4 % in terms of 
secondary antibody titres (Table 1). 
 
Delayed-type hypersensitivity (DTH) 
response  
 
CS (50 - 800 mg/kg p.o.) showed a decrease 
of 11.5 - 45.9 % in DTH response in mice. 
The most pronounced effect was observed at 
the dose of 600 mg/kg (p < 0.01). The effect 
of CS at 800 mg/kg was reduced to 44.3 %. 
Cyclosporine A (5 mg/kg) produced a 57.4 % 
decrease (Table 1). 
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Table 1: Effect of Cyperus scariosus (CS) on SRBC induced primary (Habt) and secondary (Sabt) humoral 
immune response and delayed-type hypersensitivity (DTH) or CMI response in mice. 
*
p < 0.05; 
**
p < 0.01 (Dunnett test); Habt, humoral antibody titre (primary); Sabt, secondary antibody titre; 
(↓) reduction in activity; number of animals per group=6; CMI= cell mediated immunity.  
 
Table 2: Effect of Cyperus scariosus (CS) on homologous graft rejection in mice 
 
  Group             Treatment (mg/kg)             Rejection Time (Days)      % Activity 
                                                                                  (Mean ± S.E.) 
 
 I                       Naive Control (NC)               12.00 ± 0.25                       - 
 II                      Cyclosporine-A (5)               19.00 ± 0.25**                58.33 ↑ 
III                      CS (50)                             13.00 ± 0.25                    8.33 ↑ 
IV                      CS (100)                            13.33 ± 0.21**               11.08 ↑ 
V                       CS (200)                             14.33 ± 0.21**                19.41 ↑ 
VI                      CS (400)                            15.50 ± 0.34**                29.16 ↑ 
VII                     CS (600)                           17.00 ± 0.25**                41.66 ↑ 
VIII                    CS (800)                           17.50 ± 0.34**                45.83 ↑ 
**p<0.01 (Dunnett test); n=6. 
 
Skin allograft rejection 
 
CS at 50 - 800 mg/kg delayed skin allograft 
rejection time in mice. The maximum delay in 
graft rejection was 45.8 % at 800 mg/kg (p < 
0.01). However, CS at p.o. doses ranging 
from 50 - 600 mg/kg delayed the graft 
rejection time in a dose-dependent manner 
by between 8.3 and 41.7 % as indicated in 
Table 2. 
 
In vitro phagocytic response  
 
CS was administered to mice at the doses of 
50,100, 200, 400, 600 and 800 µg/mL. The 
results are shown in Table 3. Significant 
decreases in phagocytosis of heat killed 
Candida albicans by murine macrophages 
were observed at doses of 400, 600, and 800 
µg/mL, the effect being 27.0, 37.4 and 36.6 
%, respectively (p < 0.01). This compares 
with cyclosporine A (10 µg/mL) which showed 
47.1 % decrease (p < 0.01). 
 
Ex vivo phagocytic response  
 
Administration of CS to mice over a period of 
7 days decreased the rate of clearance of 
carbon particles from circulation (Table 3). 
The decrease in phagocytic index was 4.7 -  








Paw swelling (mm) in mice day 7 
Treatment dose 
(mg/kg, p.o.) 
(Mean ± S.E.) % Change (Mean ± S.E.) % Change (Mean ± S.E.) % Change 
Control SRBC 6.83 ± 0.16 - 7.33 ± 0.21 - 0.61 ± 0.01 - 




 31.77↓ 4.66 ± 0.33
**
 36.42↓ - - 
Cyclosporine A (5) - - - - 0.26 ± 0.02
**
 57.37 ↓ 
CS (50) 6.66 ± 0.21 2.48 ↓ 7.00 ± 0.25 4.52 ↓ 0.54 ± 0.02
*
 11.47↓ 
CS (100) 6.33 ± 0.21 7.32 ↓ 6.50 ± 0.22
*
 11.32 ↓ 0.50 ± 0.02
**
 18.03 ↓ 
CS (200) 6.00 ± 0.25 12.15 ↓ 6.16 ± 0.16
**
 15.96 ↓ 0.41 ± 0.01
**
 32.78 ↓ 
CS (400) 5.66 ± 0.21
**
 17.13 ↓ 5.85 ± 0.16
**
 20.46 ↓ 0.37 ± 0.02
**
 39.34 ↓ 
CS (600) 5.00 ± 0.25
**
 26.79 ↓ 5.16 ± 0.16
**
 29.72 ↓ 0.33 ± 0.01
**
 45.90 ↓ 
CS (800) 5.33 ± 0.21
**
 21.96 ↓ 5.50 ± 0.22
**
 24.96 ↓ 0.34 ± 0.02
**
 44.26 ↓ 
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 Mean ± S.E.(%)  
 Treatment 
(dose mg/kg) 
Phagocytic Index (ex 
vivo)  
Mean ± S.E.(%) 
Naïve Control 26.44 ± 1.09 Naïve Control 1.27 ± 0.11 
Cyclosporine-A (10) 13.98 ± 0.46
**
   (47.12) ↓ Cyclosporine-A (5) 0.70 ± 0.15
**
 (44.88) ↓ 
CS (50)  25.70 ± 0.33     (2.79)   ↓ CS (50) 1.21 ± 0.10 (4.72)   ↓ 
CS (100)  24.18 ± 0.29     (8.54)   ↓ CS (100) 1.18 ± 0.28    (7.08)   ↓ 
CS (200)  21.89 ± 0.71
**
   (17.20) ↓ CS (200) 1.09 ± 0.12    (14.17) ↓ 
CS (400)  19.31 ± 0.31
**
   (26.96) ↓ CS (400) 0.92 ± 0.21
**
  (27.55) ↓ 
CS (600) 16.54 ± 1.24
**
   (37.44) ↓ CS (600) 0.80 ± 0.10
**
  (37.00) ↓ 
CS (800)  16.77 ± 0.55
**
   (36.57) ↓ CS (800) 0.79 ± 0.21
**
  (37.79) ↓ 
**
 p< 0.01 (Dunnett test); Figures in parentheses represent % change in activity; number of animals per 













Fig 1: Effect of chloroform fraction of Cyperus scariosus (CSC) on  CD8+ / ■ CD4+ T cell surface marker 
population. (**p < 0.01; NC = normal control; SC = sensitized control; CsA = cyclosporine A (5 mg/kg); CSC 
= Cyperus scariosus chloroform fraction 
 
37.8 % in the dose range of 50 - 800 mg/kg 
compared with cyclosporine A (5 mg/kg) 
which produced 44.9 % decrease (p<0.01) in 
phagocytosis. The effect was statistically 




CSC showed maximum effect at 100 mg/kg 
dose which accounted for 14.0 ± 0.4 % of 
CD8+ and 25.3 ± 0.4 % of CD4+ T cells (p < 
0.01). The control values were 22.3 ± 0.3 % 
of CD8+ and 38.6 ± 0.4 % of CD4+ T cells. 
This shows a significant suppression of CD8+ 
and CD4+ T cell population (p < 0.01). On the 
other hand, cyclosporine A (5 mg/kg), a 
standard T cell inhibitor, significantly (p < 
0.01) inhibited both CD8+ and CD4+ T cells 
by 9.2 ± 0.4 and 16.5 ± 0.4, respectively, as 
shown in Fig 1. 
 
Intracellular cytokine estimation 
 
The results of the effect of the test material 
on cytokines IL-2 and IFN-γ are displayed in 
Fig 2. Both IL-2 and IFN-γ counts were down-
regulated. The reduction in IL-2 by CSC was 
observed at all dose levels with a maximum 
expression of 23.2 ± 0.3 % in CD4+ + T cells 
(p < 0.01) at a dose of 200 mg/kg. IL-2 in the 
sensitized control group was 35.3 ± 0.5 % 
while IFN-γ decreased from 17.4 ± 0.5 
(sensitized control) to 11.4 ± 0.6 % in CSC-
treated group at a dose of 100 mg/kg (p < 
0.01). However, cyclosporine A (as standard) 
significantly  (p < 0.01)  decreased  IL-2  and  
*
*   
  
   
  
  
   
   





















Bhagwat et al  

















Fig 2:    Effect of chloroform fraction of Cyperus scariosus (CSC) on  IL-2 (□),  IFN-γ (■) and IL-4 (■) populations. 
(**p < 0.01; NC = normal control; SC = sensitized control; CsA = cyclosporine A (5 mg/kg); CSC = Cyperus 
scariosus chloroform fraction 
 
IFN-γ by 16.4 ± 0.3 and 7.7 ± 0.2 %, 
respectively (see Fig. 2). 
 
IL-4 in the normal sensitized group was 26.2 
± 0.4 %. The maximum inhibition of IL-4 in 
CD 4+ T cells was 23.4 ± 1.0 % at 100 mg/kg 
dose p.o.; this inhibition was not significant (p 
< 0.01) On the other hand, cyclosporine A-
treated group showed a significant  decrease 
(p < 0.01) in IL-4 of 11.48 ± 0.67  at a dose of 




The present study was aimed to investigate 
the immunosuppressive property of Cyperus 
scariosus and its therapeutic potential as an 
anti-inflammatory agent. The experimental 
design was in two phases. In the first phase, 
50% EtOH extract of C. scariosus (CS) was 
explored for its immunosuppressive 
properties, and this was indicated by the 
significant decrease in humoral and cell 
mediated responses. The results of 
macrophage phagocytic response confirmed 
the immunosuppressive properties of CS. 
These results prompted us to embark on the 
second phase which was to extend the 
studies to the bioactive fractions. Out of the 
three fractions obtained from CS extract 
(chloroform, n-butanol and water fractions) 
the chloroform fraction (CSC) showed 
marked immunosuppressive and anti-
inflammatory activities, as evidenced from the 
results of lymphocyte immunophenotyping of 
T cell surface markers (CD8+/CD4+), which 
were down-regulated by CSC (see Fig 1), 
and the expression of intracellular Th1 (IL-2 
and IFN-γ) and Th2 (IL-4) cytokines (as 
shown in Fig 2). T cells expressing CD4 are 
increased when the physiological systems of 
the body are stimulated due to the activation 
of the non-specific immune status, and 
inhibition of this phenomenon indicates 
immunosuppression. When the body’s 
defense mechanism is threatened by 
microorganisms or any other foreign 
invaders, macrophages are activated at the 
site of invasion to combat infections. CD 4+ T 
cell inhibition by C. scariosus may be one of 
the factors responsible for the decrease in 
the functioning of the macrophages. The 
reduced responsiveness of the phagocytes is 
evident by the decrease in the clearance of 
carbon particles from the reticuloendothelial 
system and also in the reduction in the rate of 
in vitro phagocytosis by murine 
macrophages, thus suggesting a reduction in 
the functioning of macrophages (Table 2). 
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production by CD4+ T cells in a dose-
dependent manner (Fig. 1). IL-2 is a growth 
factor for Th1 cytokines. Possibly, the 
inhibition of IL-2 is responsible for the 
reduced secretion of IFN-γ by CD 8+ T cells. 
Apart from its role in T cell activation, IFN- γ 
is known to be central to full blown activation 
of macrophages [16] and its inhibition by 
CSC may be one of the important factors 
causing reduction in macrophage function 
[17,18]. CSC did not show significant 
reduction in IL-4 expression, which suggests 
that C. scariosus has little effect on Th 2 
system. 
 
Th1/Th2 paradigm not only allows a better 
understanding of the main mechanisms 
involved in the protection and pathogenesis 
of several immunopathic disorders, but also 
provides the basis for cytokine-induced 
immune deviation. The findings outlined 
above have demonstrated that C. scariosus 
has a potent T cell suppressive activity and 
this is suggestive of its possible therapeutic 
usefulness in the treatment of inflammatory 
states of the body and auto-immune 
disorders such as arthritis. However, its 
clinical margin of safety in long-term 
therapeutics has to be established along with 
its biopharmaceutical evaluation prior to 




The findings from the present investigation 
reveal that C. scariosus causes 
immunosuppression by inhibiting Th1 
cytokines. However, it has little or no effect 
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